The dilemma of pharmacologic treatment of acute respiratory distress syndrome
10.3969/j.issn.1008-9691.2025.01.024
- VernacularTitle:急性呼吸窘迫综合征药物治疗的窘境
- Author:
Wenzhe LI
1
;
Xinxin DU
;
Xiangyou YU
Author Information
1. 新疆医科大学第一附属医院重症医学科,新疆维吾尔自治区 乌鲁木齐 830054;新疆医学动物模型研究重点实验室,新疆维吾尔自治区 乌鲁木齐 830054
- Publication Type:Journal Article
- Keywords:
Acute respiratory distress syndrome;
Phenotypes;
Precision medicine;
Clinical trials
- From:
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2025;32(1):122-126
- CountryChina
- Language:Chinese
-
Abstract:
With updates of the definition and guidelines of acute respiratory distress syndrome(ARDS),significant improvements have been made in the clinical recognition and management of ARDS.The lung-protective ventilation strategy remains the primary supportive therapy for ARDS,while the absence of specific pharmacological treatments continues to contribute to the persistently high mortality rate in ARDS patients.Evidence from studies reveals that the clinical and biological heterogeneity of ARDS is closely associated with differences in its etiology,disease severity,progression and gene expression,and also demonstrates the complex pathogenesis of ARDS.Therefore,how to optimize the treatment of this heterogeneous syndrome and break through the dilemma of pharmacologic therapies is a daily problem faced by every clinician.Based on the pathophysiological mechanism of ARDS,this review summarizes the clinical studies on pharmacological interventions targeting immune response modulation,restoration of alveolar epithelial cell function,reversal of endothelial cell and vascular dysfunction,stabilization of coagulation,and promotion of tissue repair.The aim is to optimize the clinical practice and scientific research,and provide reference for clinicians achieving the goal of personalized medicine.
